Japan's AMED names 8 projects for pre-designation orphan review

Japan's Agency for Medical Research and Development (AMED) named 8 projects for a pre-designation review as orphan drug commercialization candidates. These include three candidates from Tokyo-based Nobelpharma: N-acetylneuraminic acid for distal myopathy; NPC-14 (arbekacin sulfate) for Duchenne muscular dystrophy and a malaria vaccine. Candidates from other companies include additional indications of anticoagulant drugs from Tokyo-based Asahi Kasei Pharma; pustular psoriasis therapy from Tokyo-based SBI Biotech; GSK2315698 and GSK2398852 for systemic amyloidosis from GlaxoSmithKline ($GSK); therapeutic radiopharmaceuticals for malignant glioma from Tokyo-based Fujifilm RI Pharma; and achondroplasia therapy using anti-FGF2 aptamers from Tokyo-based Ribomic. AMED website

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.